Trial Profile

Category 3 abuse-deterrent study of the abuse-deterrent, extended-release oxycocone product Egalet 002

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxycodone (Primary)
Indications Pain
Focus Adverse reactions

Most Recent Events

16 Dec 2016 According to an Egalet media release, full data from this trial will be presented at a medical meeting in 2017.
16 Dec 2016 Results published in an Egalet Media Release
25 Aug 2016 According to an Egalet media release, the data of this trial would be presented PAINWeek 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com